Our Story
We started
with a sequence.
Every disease has one. We decode it, design against it, and target what it cannot afford to change.
Seek Labs is building a programmable disease-response platform that turns genomic intelligence into deployable therapeutics and diagnostics. One AI engine. Two deployment paths. A new way to respond to disease.
Why We Started
Built from loss.
Seek Labs began with a family that understood firsthand what it means to run out of time. That experience still shapes every decision we make: the urgency of the work, the standard we hold our science to, and the belief that better tools only matter if they reach people in time.
That urgency is why we built a platform, not a single drug or product.
We were founded on a simple thesis: disease moves faster than traditional product development. Seek Labs was built to close that gap by bringing together scientific, technical, operational, and strategic expertise to create platforms that can move from insight to deployment in the real world.
What We Believe – How We Work
The principles that shape our science, our platform, and our urgency
01
Target what the disease cannot change.
Disease evolves around biological pressure, so we focus on the conserved sequences that are essential to survival. Then we design interventions to disrupt or identify the cause at its source and give the body a clearer path to recovery.
02
Speed and precision should move together.
Traditional discovery is slow because it often starts as a search problem. BioSeeker turns discovery into a design opportunity, using genomic intelligence to identify what to target and how to respond with greater speed, precision, and purpose.
03
Preparedness should start before the outbreak.
We’ve already started. When a new threat emerges, the goal is not to begin from zero. Today, the platform is already running and we have an active repository of mapped diseases, which allows us to rapidly move from intelligence to deployment.
04
The best tools are the ones that reach people in time.
A diagnostic trapped in a centralized lab is an answer that didn’t arrive in time. A therapeutic that cannot scale will not reach the people who need it most. We design for the field, the clinic, and the stockpile, so disease response is possible in the moment of need.
Innovation & Impact Report
A year-end review of Seek Labs’ scientific progress, program execution, strategic partnerships, and operational momentum.
View the Report →Innovation & Impact Report
Our first formal innovation and impact report (formerly titled the Corporate Social Responsibility Report), highlighting how Seek Labs operates, governs, and builds with accountability.
Quality Policy
Quality drives our mission to advance global health.
We prioritize patient safety, scientific rigor, and compliance with applicable regulatory requirements through a culture of continuous improvement.
We are committed to excellence in all that we do.
Leadership
The people behind the science.
Scientists, engineers, and leaders building the future of molecular medicine.
Jared Bauer, MBA
Co-Founder & CEO
Entrepreneur and operator who scaled BurnFree into 58 countries before a successful exit. Key leader in Utah’s biotech ecosystem.
Brad Bauer
Co-Founder & CTO
36 years in executive tech leadership. Technical founder of six startups, two public. 13 U.S. patents.
Kim Wirthlin, MPA
Chief Strategy & Policy Officer
Enterprise strategist scaling biotech innovation across multi-stakeholder ecosystems. Former University of Utah leader.
Aaron Duffy, PhD
Director of Business Development
PhD biochemist from University of Utah Tech Transfer. Translates science into partnerships, licensing opportunities, and external growth.
Masami Goda, MS
Director of Quality & Regulatory
Quality and regulatory expert with 15+ years advancing products through global regulatory pathways.
Alison O’Mahony, PhD
SVP, Research and Development
Former scientific leader at Recursion and Eurofins with deep expertise in immunology and immune-oncology.
Douglas Gladue, PhD
VP, Therapeutics
Former USDA virologist and global expert in veterinary infectious diseases, vaccines, and viral pathogenesis.
Anindita “Annie” Roy, PhD
VP, Research
Global Scholar and venture associate dedicated to applying rigorous, forward-looking research and strategic insight.
Deric Holden, PhD
VP, Operations
Former leader at e-Sens driving technical product development from early concept through validation.
Anusha Pusuluri, PhD
Scientific Lead, Delivery
Founding scientist and platform lead at Mirai Bio with extrahepatic delivery experience and leadership across targeted delivery and translational R&D.
Amy Eggers, PhD
Scientific Lead, BioEngineering
CRISPR biology expert trained in Jennifer Doudna’s UC Berkeley lab; scientific and translational experience in advanced genetics.
Naveen Verma, PhD
Scientific Lead, Translational Sciences
Oncological scientist with preclinical experience at BridGene BioSciences; advancing novel therapeutics from discovery to development.
Board of Directors
Board members bring experience across diagnostics, therapeutics, innovation commercialization, and company building.
Bill Stoddart, MA
Board Chair, Co-Founder 45 North Partners
Randy Rasmussen, PhD
Co-Founder, BioFire Diagnostics
Cindy Dunkle
Genentech, Denali Therapeutics
Michael Paul, PhD
CEO, Lineagen, MARAbio
Keith Marmer, MBA, DPT
Fmr. Chief Innovation Officer, University of Utah
Pete Koson, MBA, CMA
Founder, Ninety South Consulting CFO Services
Join / Partner
Build with us.
We partner with governments, research institutions, and pharmaceutical companies. And we�re always looking for exceptional scientists and engineers to join the team.